<HTML>
<HEAD>
<TITLE>sv8</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">






<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>As filed with the Securities and Exchange Commission on February&nbsp;27, 2006</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Registration No.&nbsp;333-&#95;&#95;&#95;</B>

</DIV>

<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM S-8</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933</B>
</DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>ENCORE MEDICAL CORPORATION</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><I>(Exact name of registrant as specified in its charter)</I></DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>65-0572565</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><I>(State or other jurisdiction</I>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>(I.R.S. Employer</I></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><I>of incorporation or organization)</I>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>Identification Number)</I></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>9800 Metric Blvd.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>Austin, Texas</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>78758</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><I>(Address of principal executive offices)</I>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>(Zip Code)</I></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>ENCORE MEDICAL CORPORATION 1996 INCENTIVE STOCK PLAN<BR>
DAN GLADNEY NON-INCENTIVE STOCK OPTION AGREEMENTS DATED AUGUST 12, 2002<BR>
SCOTT YOUNGSTROM NON-INCENTIVE STOCK OPTION AGREEMENT DATED DECEMBER 9, 2002<BR>
MARSHALL MASKO NON-INCENTIVE STOCK OPTION AGREEMENT DATED NOVEMBER 25, 2002<BR>
SARAH FERGUSON STOCK OPTION AGREEMENT DATED APRIL 23, 2004<BR>
HAWK ASSOCIATES STOCK OPTION AGREEMENT DATED MARCH 1, 2004<BR>
JERRY RICE STOCK OPTION AGREEMENT DATED JULY 1, 2003</B><BR>
<I>(Full title of Plan)</I></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Harry L. Zimmerman<BR>
Executive Vice President &#150; General Counsel<BR>
Encore Medical Corporation<BR>
9800 Metric Blvd.<BR>
Austin, Texas 78758<BR>
(512)&nbsp;832-9500</B><BR>
<I>(Name, Address, including zip code and telephone<BR>
number, including area code, of agent for service)</I></DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CALCULATION OF REGISTRATION FEE
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%"></TD>
    <TD width="54%"></TD>
    <TD width="2%"></TD><!-- VRule -->
    <TD width="2%"></TD>
    <TD width="7%"></TD>
    <TD width="2%"></TD><!-- VRule -->
    <TD width="2%"></TD>
    <TD width="7%"></TD>
    <TD width="2%"></TD><!-- VRule -->
    <TD width="2%"></TD>
    <TD width="7%"></TD>
    <TD width="2%"></TD><!-- VRule -->
    <TD width="2%"></TD>
    <TD width="7%"></TD>

    <TD width="1%"></TD>
</TR><TR style="font-size: 1px" valign="bottom">
    <TD nowrap align="left" colspan="15" style="border-bottom: 3px double #000000">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">    <TD width="1%">&nbsp;</TD>

    <TD>&nbsp;</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Proposed</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Proposed</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">    <TD width="1%">&nbsp;</TD>

    <TD>&nbsp;</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Amount</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Maximum</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Maximum</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">    <TD width="1%">&nbsp;</TD>

    <TD nowrap align="center">Title of</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">to be</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Offering Price</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Aggregate</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Amount of</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">    <TD width="1%">&nbsp;</TD>

    <TD nowrap align="center">Securities to be Registered</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Registered<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Per Share</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Offering Price<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Registration Fee<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></TD>
    <TD width="1%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD width="1%" style="border-top: 2px solid #000000">&nbsp;</TD>
     <TD align="center" style="border-top: 2px solid #000000"><DIV style="margin-left:15px; text-indent:-15px">Common Stock, $.001 par
value per share</DIV></TD>
    <TD style="border-right: 2px solid #000000; border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>

<TD align="center" valign="top" style="border-top: 2px solid #000000" nowrap>957,282(2)</TD>
    <TD style="border-right: 2px solid #000000; border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 2px solid #000000">(3)</TD>
    <TD style="border-right: 2px solid #000000; border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 2px solid #000000">$2,901,537</TD>
    <TD style="border-right: 2px solid #000000; border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 2px solid #000000">$310.46</TD>
    <TD width="1%" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD width="1%" style="border-top: 0px solid #000000">&nbsp;</TD>
    <TD align="center" style="border-top: 0px solid #000000"><DIV style="margin-left:15px; text-indent:-15px">Common Stock, $.001 par
value per share</DIV></TD>
    <TD style="border-right: 2px solid #000000; border-top: 0px solid #000000">&nbsp;</TD>
    <TD style="border-top: 0px solid #000000">&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 0px solid #000000">5,000,000</TD>
    <TD style="border-right: 2px solid #000000; border-top: 0px solid #000000">&nbsp;</TD>
    <TD style="border-top: 0px solid #000000">&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 0px solid #000000">(4)</TD>
    <TD style="border-right: 2px solid #000000; border-top: 0px solid #000000">&nbsp;</TD>
    <TD style="border-top: 0px solid #000000">&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 0px solid #000000">$27,744,500</TD>
    <TD style="border-right: 2px solid #000000; border-top: 0px solid #000000">&nbsp;</TD>
    <TD style="border-top: 0px solid #000000">&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 0px solid #000000">$2,968.66</TD>
    <TD width="1%" style="border-top: 0px solid #000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px" valign="bottom">
    <TD nowrap align="left" colspan="15" style="border-top: 3px double #000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<DIV style="margin-top: 3pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">(1)</TD>
    <TD>&nbsp;</TD>
    <TD>Pursuant to Rule&nbsp;416(a), this registration statement shall also cover any additional shares
of common stock which become issuable under the Encore Medical Corporation 1996 Incentive
Stock Option Plan being registered pursuant to this registration statement by reason of any
stock dividend, stock split, recapitalization or any other similar transaction effected
without the receipt of consideration which results in an increase in the number of the
registrant&#146;s outstanding shares of common stock.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(2)</TD>
    <TD>&nbsp;</TD>
    <TD>Consists of 673,669 shares, 140,056 shares, 17,507 shares, 70,028 shares, 21,008 shares, and
35,014 shares of common stock issuable upon exercise of non-qualified options granted to Dan
Gladney, Scott Youngstrom, Marshall Masko, Sarah Ferguson, Hawk Associates, and Jerry Rice,
respectively.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(3)</TD>
    <TD>&nbsp;</TD>
    <TD>Calculated pursuant to paragraphs (c)&nbsp;and (h)&nbsp;of Rule&nbsp;457, based on the exercise price of
$2.56 to purchase 673,669 shares, $2.64 to purchase 140,056 shares, $2.76 to purchase 17,507
shares, $6.16 to purchase 70,028 shares, $6.78 to purchase 21,008 shares, and $3.34 to
purchase 35,014 shares.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(4)</TD>
    <TD>&nbsp;</TD>
    <TD>Calculated pursuant to paragraphs (c)&nbsp;and (h)&nbsp;of Rule&nbsp;457, based on the exercise price of
$4.84 of outstanding options to purchase 1,525,000 shares of Common Stock granted to officers
of Encore, and the exercise price of $5.86 of outstanding options to purchase 3,475,000 shares
of Common Stock using the average of the high and low prices reported on the Nasdaq National
Market on February&nbsp;24, 2006.</TD>
</TR>

</TABLE>
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">








<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Explanatory Note<BR>
Registration of Additional Securities</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Registration Statement on Form S-8 is filed by Encore Medical Corporation, a
Delaware corporation (&#147;we,&#148; &#147;us&#148;,&#148; &#147;our&#148; or &#147;Encore&#148;), related to shares of our common stock,
$0.001 par value per share (the &#147;Common Stock&#148;), issuable under (a)&nbsp;certain individual stock option
agreements (the &#147;Compex Option Agreements&#148;) assumed by Encore in connection with our acquisition of
Compex Technologies, Inc. (&#147;Compex&#148;) on February&nbsp;24, 2006, and (b)&nbsp;issuable under the Encore
Medical Corporation 1996 Incentive Stock Plan (the &#147;1996 Incentive Stock Plan&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U>The Compex Option Agreements</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each option to purchase Compex common stock under the Compex Option Agreements that was
outstanding and unexercised prior to the effective time of the acquisition, whether vested or
unvested, was converted into the right to acquire 1.40056 shares of Encore Common Stock (rounded
down to the nearest whole number) at an exercise price equal to the exercise price per share
specified in the individual stock option agreement divided by 1.40056 (rounded up to the nearest
full cent).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U>The 1996 Incentive Stock Plan</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We previously registered 4,500,000 shares of our common stock, $0.001 par value per share (the
&#147;Common Stock&#148;), issuable under the Encore Medical Corporation 1996 Incentive Stock Plan (the &#147;1996
Plan&#148;), pursuant to registration statements on Form S-8 (Registration Nos. 333-48240, 333-92400,
333-120024) filed on October&nbsp;19, 2000, July&nbsp;15, 2002, and October&nbsp;28, 2004 (the &#147;Prior Registration
Statements&#148;). Pursuant to General Instruction E to Form S-8 (&#147;General Instruction E&#148;), the
contents of the Prior Registration Statements are incorporated by reference herein, including the
information incorporated by reference therein, and the information required by Part&nbsp;II is omitted,
except for Items 3 and 8, which have been updated. On February&nbsp;23, 2006, our stockholders
authorized the issuance of an additional 5,000,000 shares of our Common Stock under the 1996 Plan.
We are registering the additional 5,000,000 shares of our Common Stock issuable under the 1996 Plan
pursuant to this registration statement (the &#147;Registration Statement&#148;). As a result, the total
number of shares of common stock registered under the 1996 Plan is 9,500,000.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PART I</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Item&nbsp;1. Plan Information.*</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Item&nbsp;2. Registrant Information and Employee Plan Annual Information.*</B>

</DIV>

<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>

<DIV style="margin-top: 3pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">*</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Information required by Part&nbsp;I of Form S-8 to be contained in a prospectus meeting the
requirements of Section 10(a) of the Securities Act of 1933 is omitted from this Registration
Statement in accordance with Rule&nbsp;428 under the Securities Act of 1933 and the Note to Part&nbsp;I
of Form S-8.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PART II</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Item&nbsp;3. Incorporation of Documents by Reference.</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We incorporate by reference into this Registration Statement the following documents filed by
us with the Securities and Exchange Commission (the &#147;<U>Commission</U>&#148;):
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Our Annual Report on Form 10-K (File No.&nbsp;000-26538) for the fiscal year ended December&nbsp;31,
2004, filed March&nbsp;16, 2005;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All other reports filed by us pursuant to Sections 13(a) or 15(d) of the Securities Exchange
Act of 1934, as amended (the &#147;Exchange Act&#148;) since December&nbsp;31, 2004, including our Current
Report on Form 8-K (File No.&nbsp;000-26538) filed on February&nbsp;4, 2005; the Current Report on Form
8-K/A filed on February&nbsp;18, 2005; the Current Report on Form 8-K filed on February&nbsp;28, 2005;
the Current Report on Form 8-K filed on May&nbsp;2, 2005; the Quarterly Report on Form 10-Q for the
fiscal quarter ended April&nbsp;2, 2005, filed on May&nbsp;11, 2005; the Current Report on Form 8-K
filed on June&nbsp;1, 2005; the Current Report on Form 8-K filed on August&nbsp;1, 2005; the Current
Report on Form 8-K filed on August&nbsp;9, 2005; the Quarterly Report on Form 10-Q for the fiscal
quarter ended July&nbsp;2, 2005, filed on August&nbsp;10, 2005; the Current Report on Form 8-K filed on
October&nbsp;31, 2005; the Quarterly Report on Form 10-Q for the fiscal quarter ended October&nbsp;1,
2005, filed on November&nbsp;9, 2005; the Current Report on Form 8-K filed on November&nbsp;15, 2005;
the Current Report on Form 8-K filed on December&nbsp;1, 2005; the Current Report on Form 8-K filed
on December&nbsp;19, 2005; the Current Report on Form 8-K filed on January, 23, 2006; and the
Current Reports on Form 8-K filed on February&nbsp;27, 2006.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The description of Encore Common Stock contained in our Registration Statement on Form 8-K,
filed with the Commission on July&nbsp;19, 2004.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All documents filed with the Commission pursuant to Section&nbsp;13(a), 13(c), 14 and 15(d) of the
Exchange Act subsequent to the date of this Registration Statement and prior to the filing of a
post-effective amendment that indicates that all securities offered have been sold or that
deregisters all securities then remaining unsold, shall be deemed to be incorporated herein by
reference and to be a part hereof from the date of filing of such documents.
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Item&nbsp;6. Indemnification of Directors and Officers</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Delaware General Corporation Law</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;145 of the Delaware General Corporation Law (&#147;Section&nbsp;145&#148;) permits indemnification
of, and advancement of expenses to, directors, officers, employees and agents of a corporation
under certain conditions and subject to certain limitations, as set forth below. Such
indemnification and advancement of expenses may be continued even if a person ceases to serve as a
director, officer, employee or agent of the corporation and may inure to such person&#146;s heirs,
executors or administrators.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;145 (a)&nbsp;empowers a corporation to indemnify any person who is or was a party or is
threatened to be made a party to any threatened, pending, or completed action, suit or proceeding,
whether civil, criminal, administrative or investigative, other than an action by or in the right
of a corporation, by reason of the fact that he is or was a director, officer, employee or agent of
the corporation, or any other enterprise if he is or was serving such enterprise at the request of
the corporation. A corporation may indemnify such person against expenses (including attorneys&#146;
fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in
connection with an action, suit or proceeding, if such person acted in good faith and in a manner
he reasonably believed to be in, or not opposed to, the best interests of the corporation, and,
with respect to any criminal action or proceeding, if he had no reasonable cause to believe his
conduct was unlawful. The termination of a suit, action or other proceeding, or the entry of a
plea of nolo contenders, or its equivalent, does not of itself create a presumption, under Section
145, that the person to be indemnified did not act in good faith, in a manner he reasonably
believed to be in or not opposed to the best interests of the corporation, or in the case of a
criminal action, that he had reasonable cause to believe his conduct was unlawful.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under Section&nbsp;145(b), the indemnification a corporation may offer is extended to include
indemnification for expenses (including attorneys&#146; fees) actually and reasonably incurred in
connection with the defense or settlement of an action by or in the right of a corporation, to
procure a judgment in its favor, as long as the director, officer, employee or agent to be
indemnified acted in good faith and in a manner he reasonably believed to be in or not opposed to
the best interests of the corporation; provided, however, that such indemnification may not be
extended to cover any claim, issue, or matter as to which such person shall have been adjudged to
be liable to the corporation unless, and only to the extent that, the Court of Chancery, or such
other court in which the action, suit or proceeding was brought, shall determine upon application
that despite the adjudication of liability but in view of all the circumstances of the case, such
person is fairly and reasonably entitled to indemnification for such expenses as the court deems
proper. In addition, Section&nbsp;145 (c)&nbsp;provides for mandatory indemnification by a corporation,
including indemnification for expenses (including attorneys&#146; fees) actually and reasonably incurred
by a director, officer, employee or agent of the corporation, in the event that such person is
successful on the merits or in defense of any covered action, or in defense of any claim, issue or
matter therein.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A corporation may indemnify a director, officer, employee or agent only as authorized in the
specific instance and only upon a determination that indemnification is proper, given the facts and
circumstances, because that person has met the applicable standard of conduct set forth in Sections
145(a) and (b). Section&nbsp;145 (d)&nbsp;states that such a determination may be made by a majority vote of
the directors who are not parties to such action, suit or proceeding, even though the directors
able to vote do not constitute a quorum, or in the absence of any directors able to vote or at the
direction of such directors, by independent legal counsel in a written opinion, or by the
stockholders of the corporation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to Section&nbsp;145 (e), a corporation may indemnify an officer or director defending a
civil, criminal, administrative or investigative action, suit or proceeding in advance of the final
disposition of such action, suit or proceeding if it receives from such person or from another on
behalf of such person, an
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">undertaking to repay any amount paid in advance if that person is
ultimately determined not to be entitled to indemnification.
Expenses incurred by other employees and agents may be so paid upon terms and conditions
deemed appropriate by the board of directors of a corporation. Pursuant to Section&nbsp;145 (k), the
Delaware Court of Chancery may summarily determine a corporation&#146;s obligation to advance expenses
(including attorneys&#146; fees).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under Section&nbsp;145 (f), the indemnification and advancement of expenses provided for by statute
is not to be deemed exclusive of the other rights persons seeking indemnification or advancement of
expenses may have under any bylaw, agreement, vote of stockholders or disinterested directors or
otherwise, both as to actions taken in an official capacity and as to actions taken in another
capacity while holding such office.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;145 (g)&nbsp;grants a corporation power to purchase and maintain an insurance policy
insuring any person who is or was a director, officer, employee or agent of the corporation or who
is or was serving in such capacity for another corporation, partnership, joint venture, trust or
other enterprise at the request of the corporation, which policy may insure any liability asserted
against the insured in any such capacity, or arising out of his status, regardless of whether the
corporation would otherwise have the power under Delaware law to indemnify him against such
liability.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;145 (h)&nbsp;states that the power to indemnify granted to any &#147;corporation&#148; extends to any
constituent corporation absorbed in a consolidation or merger which, had its separate existence
continued, would have been authorized to extend indemnification to its officers, directors, agents
and employees. Pursuant to Section&nbsp;145(i), employee benefit plans are covered as &#147;other
enterprises&#148; and service at the request of the corporation includes service, as a director,
officer, employee or agent of the corporation, which imposes duties on or involves services
supplied by, such person with respect to an employee benefit plan, its beneficiaries or
participants.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Delaware Court of Chancery is vested with exclusive jurisdiction to hear and determine
actions for indemnification or advancement of expenses brought under Section&nbsp;145 or under any
bylaw, agreement, vote of stockholders or disinterested directors or otherwise.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Certificate of Incorporation and Bylaws</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Certificate of Incorporation, as amended, provides, in Article&nbsp;Eighth, for indemnification
to the fullest extent permitted by Delaware law, specifically providing for the advancement of
expenses in accordance with Section&nbsp;145(e). Moreover, our Certificate of Incorporation provides
that a director of the corporation shall not be liable to the corporation or its stockholders for
monetary damages for breach of a fiduciary duty as a director, except for liability for any breach
of that director&#146;s duty of loyalty to the corporation or its stockholders, acts or omissions not in
good faith or that involve intentional misconduct or knowing violation of law, violations of
Section&nbsp;174 of the Delaware General Corporation Law, which regulates directors&#146; liability for
unlawful payments of dividends and unlawful stock purchases and redemptions, and liability for any
actions from which the director derived an improper personal benefit.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Bylaws, as currently in effect, set forth the provisions of Section&nbsp;145 and, thus, also
provide for indemnification to the full extent of Delaware law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insurance Policy
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently maintain an insurance policy providing reimbursement of indemnification payments
to our officers and directors and reimbursement of certain liabilities incurred by our directors
and officers in their capacities as such, to the extent that we do not indemnify them.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Item&nbsp;8. Exhibits.</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="87%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Exhibit Number</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Description</TD>
</TR>
<TR>    <TD>&nbsp;</TD></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Certificate of Incorporation of Encore Medical Corporation, as amended,
including Certificate of Designations, Preferences and Limitations of Series
A Preferred Stock (incorporated herein by reference to Exhibit&nbsp;3.1 of the
Encore&#146;s Form&nbsp;8-K filed with the Commission on July&nbsp;19, 2004).</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Bylaws of Encore Medical Corporation (incorporated herein by reference to
Exhibit&nbsp;3.2 of Encore&#146;s Form&nbsp;8-K filed with the Commission on July&nbsp;19,
2004).</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.3
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of certificate evidencing ownership of the Common Stock of Encore
Medical Corporation (incorporated herein by reference to Exhibit&nbsp;4.7 of
Encore&#146;s 10-K filed with the Commission on March&nbsp;30, 1998).</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.4
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Non-Incentive Stock Option Agreement dated as of August&nbsp;14, 2002 between
Compex Technologies, Inc. and Dan Gladney (incorporated by reference to
Exhibit&nbsp;10.12 to the Compex Technologies, Inc. Annual Report on Form&nbsp;10-K
for the year ended June&nbsp;30, 2003).</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.5
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Non-Incentive Stock Option Agreement (with acceleration) dated as of August
14, 2002 between Compex Technologies, Inc. and Dan Gladney (incorporated by
reference to Exhibit&nbsp;10.13 to the Compex Technologies, Inc. Annual Report on
Form&nbsp;10-K for the year ended June&nbsp;30, 2003).</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.6
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Non-Incentive Stock Option Agreement for Scott Youngstrom and
Marshall Masko.</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.7
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Non-Incentive Stock Option Agreement, dated March&nbsp;1, 2004 between Compex
Technologies, Inc. and Hawk Associates.</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.8
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Non-Incentive Stock Option Agreement, dated April&nbsp;23, 2004 between Compex
Technologies, Inc. and Sarah Ferguson.</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.9
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Non-Incentive Stock Option Agreement, dated July&nbsp;1, 2003 between Compex
Technologies, Inc. and Jerry Rice.</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">5.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Opinion of Winstead Sechrest &#038; Minick P.C. regarding the validity of the
securities being registered.</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">23.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Consent of Winstead Sechrest &#038; Minick P.C. (included as part of Exhibit&nbsp;5.1).</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">23.2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Consent of KPMG LLP.</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">24.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Power of Attorney (contained on the signature page of this registration
statement).</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Item&nbsp;9. Undertakings.</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>We hereby undertake:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To file, during any period in which offers or sales are being made, a
post-effective amendment to this Registration Statement:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to include any prospectus required by Section&nbsp;10(a)(3) of the
Securities Act of 1933;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to reflect in the prospectus any facts or events arising after
the effective date of this Registration Statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate,
represent a fundamental change in the information set forth in this
Registration Statement. Notwithstanding the foregoing, any increase or
decrease in volume of securities offered (if the total dollar value of
securities offered would not exceed that which was registered) and any
deviation from the low or high end of the estimated maximum offering range may
be reflected in the form of prospectus filed with the Commission pursuant to
Rule 424(b) if, in the aggregate, the changes in volume and price represent no
more than a 20% change in the maximum aggregate offering price set forth in the
&#147;Calculation of Registration Fee&#148; table in the effective registration
statement;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to include any material information with respect to the plan
of distribution not previously disclosed in this Registration Statement or any
material change to such information in this Registration Statement;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><I>&nbsp;</I></TD>
    <TD width="1%"><I>&nbsp;</I></TD>
    <TD><I>provided, however</I>, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the
information required to be included in a post-effective amendment by those
paragraphs is contained in periodic reports filed by us pursuant to Section&nbsp;13 or
Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by
reference in this Registration Statement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>That, for the purpose of determining any liability under the Securities Act of
1933, each such post-effective amendment shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial bona fide offering thereof.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To remove from registration by means of a post-effective amendment any of the
securities being registered which remain unsold at the termination of the offering.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(b)&nbsp;We hereby undertake that, for purposes of determining any liability under the Securities Act of
1933, each filing of our annual report pursuant to Section 13(a) or Section 15(d) of the Securities
Exchange Act of 1934 that is incorporated by reference in this Registration Statement shall be
deemed to be a new registration statement relating to the securities offered herein, and the
offering of such securities at that time shall be deemed to be the initial bona fide offering
thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(c)&nbsp;Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be
permitted to our directors, officers and controlling persons pursuant to the foregoing provisions,
or otherwise, we have been advised that in the opinion of the Securities and Exchange Commission
such indemnification is against public policy as expressed in the Securities Act of 1933 and is,
therefore, unenforceable. In the event that a claim for indemnification against such liabilities
(other than the payment by us of expenses incurred or paid by one of our directors, officers or
controlling persons in the successful defense of any action, suit or proceeding) is asserted by
such director, officer or controlling person in connection with the securities being registered, we
will, unless in the
opinion of our counsel the matter has been settled by controlling precedent, submit to a court
of
appropriate jurisdiction the question whether such indemnification by it is against public policy
as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such
issue.
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it
has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and
has duly caused this Registration Statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of Austin, State of Texas on February&nbsp;27, 2006.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">ENCORE MEDICAL CORPORATION<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Harry L. Zimmerman
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Harry L. Zimmerman&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Executive Vice President&#151;General Counsel&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each person whose signature appears below authorizes Kenneth W. Davidson or Harry L. Zimmerman
to execute in the name of each such person who is then an officer or director of the Registrant,
and to file any amendments to this Registration Statement necessary or advisable to enable the
Registrant to comply with the Securities Act of 1933, as amended, and any rules, regulations and
requirements of the Securities and Exchange Commission, in respect thereof, in connection with the
registration of the securities that are the subject of this Registration Statement, which
amendments may make such changes to such Registration Statement as such attorney may deem
appropriate.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration
Statement has been signed by the following persons in the capacities indicated on February&nbsp;27,
2006.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="26%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="69%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center"><B>SIGNATURE</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>TITLE</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Kenneth W. Davidson
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Chairman of the Board, Chief Executive Officer and Director</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="1" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Kenneth W. Davidson
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Principal Executive Officer)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ William W. Burke
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Executive Vice President&#151;Chief Financial Officer</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="1" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">William W. Burke
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Principal Financial Officer and Principal Accounting Officer)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Alastair J. Clemow
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Director</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="1" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Alastair J. Clemow</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Joel S. Kanter
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Joel S. Kanter
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Director</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Richard O. Martin
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Richard O. Martin
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Director</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Karen R. Osar
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Karen R. Osar
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Director</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Zubeen Shroff
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Director</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Bruce Wesson
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Director</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>


<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXHIBIT INDEX</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="83%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Exhibit Number</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Description</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;4.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Certificate of Incorporation of Encore Medical Corporation, as amended, including
Certificate of Designations, Preferences and Limitations of Series&nbsp;A Preferred
Stock (incorporated herein by reference to Exhibit&nbsp;3.1 of Encore&#146;s Form&nbsp;8-K filed
with the Commission on July&nbsp;19, 2004).</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;4.2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Bylaws of Encore Medical Corporation (incorporated herein by reference to Exhibit
3.2 of Encore&#146;s Form&nbsp;8-K filed with the Commission on July&nbsp;19, 2004).</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;4.3
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of certificate evidencing ownership of the Common Stock of Encore Medical
Corporation (incorporated herein by reference to Exhibit&nbsp;4.7 of Encore&#146;s 10-K
filed with the Commission on March&nbsp;30, 1998).</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;4.4
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Non-Incentive Stock Option Agreement dated as of August&nbsp;14, 2002 between Compex
Technologies, Inc. and Dan Gladney (incorporated by reference to Exhibit&nbsp;10.12 to
the Compex Technologies, Inc. Annual Report on Form&nbsp;10-K for the year ended June
30, 2003).</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;4.5
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Non-Incentive Stock Option Agreement (with acceleration) dated as of August&nbsp;14,
2002 between Compex Technologies, Inc. and Dan Gladney (incorporated by reference
to Exhibit&nbsp;10.13 to the Compex Technologies, Inc. Annual Report on Form&nbsp;10-K for
the year ended June&nbsp;30, 2003).</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;4.6
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Non-Incentive Stock Option Agreement for Scott Youngstrom and Marshall
Masko.</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;4.7
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Non-Incentive Stock Option Agreement, dated March&nbsp;1, 2004 between Compex
Technologies, Inc. and Hawk Associates.</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;4.8
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Non-Incentive Stock Option Agreement, dated April&nbsp;23, 2004 between Compex
Technologies, Inc. and Sarah Ferguson.</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;4.9
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Non-Incentive Stock Option Agreement, dated July&nbsp;1, 2003 between Compex
Technologies, Inc. and Jerry Rice.</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;5.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Opinion of Winstead Sechrest &#038; Minick P.C. regarding the validity of the
securities being registered.</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">23.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Consent of Winstead Sechrest &#038; Minick P.C. (included as part of Exhibit&nbsp;5.1).</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">23.2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Consent of KPMG LLP.</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">24.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Power of Attorney (contained on the signature page of this registration statement).</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

</BODY>
</HTML>
[{"type": "S-8", "sequence": "1", "filename": "d33462sv8.htm", "description": "FORM S-8", "secsgml_size_bytes": 62968}]
{"company-data": {"conformed-name": "ENCORE MEDICAL CORP", "cik": "0000944763", "assigned-sic": "3842", "irs-number": "650572565", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-132057", "film-number": "06646683"}, "business-address": {"street1": "9800 METRIC BOULEVARD", "city": "AUSTIN", "state": "TX", "zip": "78758", "phone": "5128329500"}, "mail-address": {"street1": "9800 METRIC BOULEVARD", "city": "AUSTIN", "state": "TX", "zip": "78758"}, "former-company": {"former-conformed-name": "HEALTHCARE ACQUISITION CORP", "date-changed": "19950531"}}
sv8
As filed with the Securities and Exchange Commission on February 27, 2006
Registration No. 333-___
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
ENCORE MEDICAL CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
65-0572565
(State or other jurisdiction
(I.R.S. Employer
of incorporation or organization)
Identification Number)
9800 Metric Blvd.
Austin, Texas
78758
(Address of principal executive offices)
(Zip Code)
ENCORE MEDICAL CORPORATION 1996 INCENTIVE STOCK PLAN
DAN GLADNEY NON-INCENTIVE STOCK OPTION AGREEMENTS DATED AUGUST 12, 2002
SCOTT YOUNGSTROM NON-INCENTIVE STOCK OPTION AGREEMENT DATED DECEMBER 9, 2002
MARSHALL MASKO NON-INCENTIVE STOCK OPTION AGREEMENT DATED NOVEMBER 25, 2002
SARAH FERGUSON STOCK OPTION AGREEMENT DATED APRIL 23, 2004
HAWK ASSOCIATES STOCK OPTION AGREEMENT DATED MARCH 1, 2004
JERRY RICE STOCK OPTION AGREEMENT DATED JULY 1, 2003
(Full title of Plan)
Harry L. Zimmerman
Executive Vice President – General Counsel
Encore Medical Corporation
9800 Metric Blvd.
Austin, Texas 78758
(512) 832-9500
(Name, Address, including zip code and telephone
number, including area code, of agent for service)
CALCULATION OF REGISTRATION FEE
Proposed
Proposed
Amount
Maximum
Maximum
Title of
to be
Offering Price
Aggregate
Amount of
Securities to be Registered
Registered
(1)
Per Share
Offering Price
(1)
Registration Fee
(1)
Common Stock, $.001 par
value per share
957,282(2)
(3)
$2,901,537
$310.46
Common Stock, $.001 par
value per share
5,000,000
(4)
$27,744,500
$2,968.66
(1)
Pursuant to Rule 416(a), this registration statement shall also cover any additional shares
of common stock which become issuable under the Encore Medical Corporation 1996 Incentive
Stock Option Plan being registered pursuant to this registration statement by reason of any
stock dividend, stock split, recapitalization or any other similar transaction effected
without the receipt of consideration which results in an increase in the number of the
registrant's outstanding shares of common stock.
(2)
Consists of 673,669 shares, 140,056 shares, 17,507 shares, 70,028 shares, 21,008 shares, and
35,014 shares of common stock issuable upon exercise of non-qualified options granted to Dan
Gladney, Scott Youngstrom, Marshall Masko, Sarah Ferguson, Hawk Associates, and Jerry Rice,
respectively.
(3)
Calculated pursuant to paragraphs (c) and (h) of Rule 457, based on the exercise price of
$2.56 to purchase 673,669 shares, $2.64 to purchase 140,056 shares, $2.76 to purchase 17,507
shares, $6.16 to purchase 70,028 shares, $6.78 to purchase 21,008 shares, and $3.34 to
purchase 35,014 shares.
(4)
Calculated pursuant to paragraphs (c) and (h) of Rule 457, based on the exercise price of
$4.84 of outstanding options to purchase 1,525,000 shares of Common Stock granted to officers
of Encore, and the exercise price of $5.86 of outstanding options to purchase 3,475,000 shares
of Common Stock using the average of the high and low prices reported on the Nasdaq National
Market on February 24, 2006.
Explanatory Note
Registration of Additional Securities
This Registration Statement on Form S-8 is filed by Encore Medical Corporation, a
Delaware corporation ("we," "us"," "our" or "Encore"), related to shares of our common stock,
$0.001 par value per share (the "Common Stock"), issuable under (a) certain individual stock option
agreements (the "Compex Option Agreements") assumed by Encore in connection with our acquisition of
Compex Technologies, Inc. ("Compex") on February 24, 2006, and (b) issuable under the Encore
Medical Corporation 1996 Incentive Stock Plan (the "1996 Incentive Stock Plan").
The Compex Option Agreements
Each option to purchase Compex common stock under the Compex Option Agreements that was
outstanding and unexercised prior to the effective time of the acquisition, whether vested or
unvested, was converted into the right to acquire 1.40056 shares of Encore Common Stock (rounded
down to the nearest whole number) at an exercise price equal to the exercise price per share
specified in the individual stock option agreement divided by 1.40056 (rounded up to the nearest
full cent).
The 1996 Incentive Stock Plan
We previously registered 4,500,000 shares of our common stock, $0.001 par value per share (the
"Common Stock"), issuable under the Encore Medical Corporation 1996 Incentive Stock Plan (the "1996
Plan"), pursuant to registration statements on Form S-8 (Registration Nos. 333-48240, 333-92400,
333-120024) filed on October 19, 2000, July 15, 2002, and October 28, 2004 (the "Prior Registration
Statements"). Pursuant to General Instruction E to Form S-8 ("General Instruction E"), the
contents of the Prior Registration Statements are incorporated by reference herein, including the
information incorporated by reference therein, and the information required by Part II is omitted,
except for Items 3 and 8, which have been updated. On February 23, 2006, our stockholders
authorized the issuance of an additional 5,000,000 shares of our Common Stock under the 1996 Plan.
We are registering the additional 5,000,000 shares of our Common Stock issuable under the 1996 Plan
pursuant to this registration statement (the "Registration Statement"). As a result, the total
number of shares of common stock registered under the 1996 Plan is 9,500,000.
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
Item 1. Plan Information.*
Item 2. Registrant Information and Employee Plan Annual Information.*
*
Information required by Part I of Form S-8 to be contained in a prospectus meeting the
requirements of Section 10(a) of the Securities Act of 1933 is omitted from this Registration
Statement in accordance with Rule 428 under the Securities Act of 1933 and the Note to Part I
of Form S-8.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
We incorporate by reference into this Registration Statement the following documents filed by
us with the Securities and Exchange Commission (the "
Commission
"):
(a)
Our Annual Report on Form 10-K (File No. 000-26538) for the fiscal year ended December 31,
2004, filed March 16, 2005;
(b)
All other reports filed by us pursuant to Sections 13(a) or 15(d) of the Securities Exchange
Act of 1934, as amended (the "Exchange Act") since December 31, 2004, including our Current
Report on Form 8-K (File No. 000-26538) filed on February 4, 2005; the Current Report on Form
8-K/A filed on February 18, 2005; the Current Report on Form 8-K filed on February 28, 2005;
the Current Report on Form 8-K filed on May 2, 2005; the Quarterly Report on Form 10-Q for the
fiscal quarter ended April 2, 2005, filed on May 11, 2005; the Current Report on Form 8-K
filed on June 1, 2005; the Current Report on Form 8-K filed on August 1, 2005; the Current
Report on Form 8-K filed on August 9, 2005; the Quarterly Report on Form 10-Q for the fiscal
quarter ended July 2, 2005, filed on August 10, 2005; the Current Report on Form 8-K filed on
October 31, 2005; the Quarterly Report on Form 10-Q for the fiscal quarter ended October 1,
2005, filed on November 9, 2005; the Current Report on Form 8-K filed on November 15, 2005;
the Current Report on Form 8-K filed on December 1, 2005; the Current Report on Form 8-K filed
on December 19, 2005; the Current Report on Form 8-K filed on January, 23, 2006; and the
Current Reports on Form 8-K filed on February 27, 2006.
(c)
The description of Encore Common Stock contained in our Registration Statement on Form 8-K,
filed with the Commission on July 19, 2004.
All documents filed with the Commission pursuant to Section 13(a), 13(c), 14 and 15(d) of the
Exchange Act subsequent to the date of this Registration Statement and prior to the filing of a
post-effective amendment that indicates that all securities offered have been sold or that
deregisters all securities then remaining unsold, shall be deemed to be incorporated herein by
reference and to be a part hereof from the date of filing of such documents.
Item 6. Indemnification of Directors and Officers
(a)
Delaware General Corporation Law
Section 145 of the Delaware General Corporation Law ("Section 145") permits indemnification
of, and advancement of expenses to, directors, officers, employees and agents of a corporation
under certain conditions and subject to certain limitations, as set forth below. Such
indemnification and advancement of expenses may be continued even if a person ceases to serve as a
director, officer, employee or agent of the corporation and may inure to such person's heirs,
executors or administrators.
Section 145 (a) empowers a corporation to indemnify any person who is or was a party or is
threatened to be made a party to any threatened, pending, or completed action, suit or proceeding,
whether civil, criminal, administrative or investigative, other than an action by or in the right
of a corporation, by reason of the fact that he is or was a director, officer, employee or agent of
the corporation, or any other enterprise if he is or was serving such enterprise at the request of
the corporation. A corporation may indemnify such person against expenses (including attorneys'
fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in
connection with an action, suit or proceeding, if such person acted in good faith and in a manner
he reasonably believed to be in, or not opposed to, the best interests of the corporation, and,
with respect to any criminal action or proceeding, if he had no reasonable cause to believe his
conduct was unlawful. The termination of a suit, action or other proceeding, or the entry of a
plea of nolo contenders, or its equivalent, does not of itself create a presumption, under Section
145, that the person to be indemnified did not act in good faith, in a manner he reasonably
believed to be in or not opposed to the best interests of the corporation, or in the case of a
criminal action, that he had reasonable cause to believe his conduct was unlawful.
Under Section 145(b), the indemnification a corporation may offer is extended to include
indemnification for expenses (including attorneys' fees) actually and reasonably incurred in
connection with the defense or settlement of an action by or in the right of a corporation, to
procure a judgment in its favor, as long as the director, officer, employee or agent to be
indemnified acted in good faith and in a manner he reasonably believed to be in or not opposed to
the best interests of the corporation; provided, however, that such indemnification may not be
extended to cover any claim, issue, or matter as to which such person shall have been adjudged to
be liable to the corporation unless, and only to the extent that, the Court of Chancery, or such
other court in which the action, suit or proceeding was brought, shall determine upon application
that despite the adjudication of liability but in view of all the circumstances of the case, such
person is fairly and reasonably entitled to indemnification for such expenses as the court deems
proper. In addition, Section 145 (c) provides for mandatory indemnification by a corporation,
including indemnification for expenses (including attorneys' fees) actually and reasonably incurred
by a director, officer, employee or agent of the corporation, in the event that such person is
successful on the merits or in defense of any covered action, or in defense of any claim, issue or
matter therein.
A corporation may indemnify a director, officer, employee or agent only as authorized in the
specific instance and only upon a determination that indemnification is proper, given the facts and
circumstances, because that person has met the applicable standard of conduct set forth in Sections
145(a) and (b). Section 145 (d) states that such a determination may be made by a majority vote of
the directors who are not parties to such action, suit or proceeding, even though the directors
able to vote do not constitute a quorum, or in the absence of any directors able to vote or at the
direction of such directors, by independent legal counsel in a written opinion, or by the
stockholders of the corporation.
Pursuant to Section 145 (e), a corporation may indemnify an officer or director defending a
civil, criminal, administrative or investigative action, suit or proceeding in advance of the final
disposition of such action, suit or proceeding if it receives from such person or from another on
behalf of such person, an
undertaking to repay any amount paid in advance if that person is
ultimately determined not to be entitled to indemnification.
Expenses incurred by other employees and agents may be so paid upon terms and conditions
deemed appropriate by the board of directors of a corporation. Pursuant to Section 145 (k), the
Delaware Court of Chancery may summarily determine a corporation's obligation to advance expenses
(including attorneys' fees).
Under Section 145 (f), the indemnification and advancement of expenses provided for by statute
is not to be deemed exclusive of the other rights persons seeking indemnification or advancement of
expenses may have under any bylaw, agreement, vote of stockholders or disinterested directors or
otherwise, both as to actions taken in an official capacity and as to actions taken in another
capacity while holding such office.
Section 145 (g) grants a corporation power to purchase and maintain an insurance policy
insuring any person who is or was a director, officer, employee or agent of the corporation or who
is or was serving in such capacity for another corporation, partnership, joint venture, trust or
other enterprise at the request of the corporation, which policy may insure any liability asserted
against the insured in any such capacity, or arising out of his status, regardless of whether the
corporation would otherwise have the power under Delaware law to indemnify him against such
liability.
Section 145 (h) states that the power to indemnify granted to any "corporation" extends to any
constituent corporation absorbed in a consolidation or merger which, had its separate existence
continued, would have been authorized to extend indemnification to its officers, directors, agents
and employees. Pursuant to Section 145(i), employee benefit plans are covered as "other
enterprises" and service at the request of the corporation includes service, as a director,
officer, employee or agent of the corporation, which imposes duties on or involves services
supplied by, such person with respect to an employee benefit plan, its beneficiaries or
participants.
The Delaware Court of Chancery is vested with exclusive jurisdiction to hear and determine
actions for indemnification or advancement of expenses brought under Section 145 or under any
bylaw, agreement, vote of stockholders or disinterested directors or otherwise.
(b)
Certificate of Incorporation and Bylaws
Our Certificate of Incorporation, as amended, provides, in Article Eighth, for indemnification
to the fullest extent permitted by Delaware law, specifically providing for the advancement of
expenses in accordance with Section 145(e). Moreover, our Certificate of Incorporation provides
that a director of the corporation shall not be liable to the corporation or its stockholders for
monetary damages for breach of a fiduciary duty as a director, except for liability for any breach
of that director's duty of loyalty to the corporation or its stockholders, acts or omissions not in
good faith or that involve intentional misconduct or knowing violation of law, violations of
Section 174 of the Delaware General Corporation Law, which regulates directors' liability for
unlawful payments of dividends and unlawful stock purchases and redemptions, and liability for any
actions from which the director derived an improper personal benefit.
Our Bylaws, as currently in effect, set forth the provisions of Section 145 and, thus, also
provide for indemnification to the full extent of Delaware law.
Insurance Policy
We currently maintain an insurance policy providing reimbursement of indemnification payments
to our officers and directors and reimbursement of certain liabilities incurred by our directors
and officers in their capacities as such, to the extent that we do not indemnify them.
Item 8. Exhibits.
Exhibit Number
Description
4.1
Certificate of Incorporation of Encore Medical Corporation, as amended,
including Certificate of Designations, Preferences and Limitations of Series
A Preferred Stock (incorporated herein by reference to Exhibit 3.1 of the
Encore's Form 8-K filed with the Commission on July 19, 2004).
4.2
Bylaws of Encore Medical Corporation (incorporated herein by reference to
Exhibit 3.2 of Encore's Form 8-K filed with the Commission on July 19,
2004).
4.3
Form of certificate evidencing ownership of the Common Stock of Encore
Medical Corporation (incorporated herein by reference to Exhibit 4.7 of
Encore's 10-K filed with the Commission on March 30, 1998).
4.4
Non-Incentive Stock Option Agreement dated as of August 14, 2002 between
Compex Technologies, Inc. and Dan Gladney (incorporated by reference to
Exhibit 10.12 to the Compex Technologies, Inc. Annual Report on Form 10-K
for the year ended June 30, 2003).
4.5
Non-Incentive Stock Option Agreement (with acceleration) dated as of August
14, 2002 between Compex Technologies, Inc. and Dan Gladney (incorporated by
reference to Exhibit 10.13 to the Compex Technologies, Inc. Annual Report on
Form 10-K for the year ended June 30, 2003).
4.6
Form of Non-Incentive Stock Option Agreement for Scott Youngstrom and
Marshall Masko.
4.7
Non-Incentive Stock Option Agreement, dated March 1, 2004 between Compex
Technologies, Inc. and Hawk Associates.
4.8
Non-Incentive Stock Option Agreement, dated April 23, 2004 between Compex
Technologies, Inc. and Sarah Ferguson.
4.9
Non-Incentive Stock Option Agreement, dated July 1, 2003 between Compex
Technologies, Inc. and Jerry Rice.
5.1
Opinion of Winstead Sechrest & Minick P.C. regarding the validity of the
securities being registered.
23.1
Consent of Winstead Sechrest & Minick P.C. (included as part of Exhibit 5.1).
23.2
Consent of KPMG LLP.
24.1
Power of Attorney (contained on the signature page of this registration
statement).
Item 9. Undertakings.
(a)
We hereby undertake:
(1)
To file, during any period in which offers or sales are being made, a
post-effective amendment to this Registration Statement:
(i)
to include any prospectus required by Section 10(a)(3) of the
Securities Act of 1933;
(ii)
to reflect in the prospectus any facts or events arising after
the effective date of this Registration Statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate,
represent a fundamental change in the information set forth in this
Registration Statement. Notwithstanding the foregoing, any increase or
decrease in volume of securities offered (if the total dollar value of
securities offered would not exceed that which was registered) and any
deviation from the low or high end of the estimated maximum offering range may
be reflected in the form of prospectus filed with the Commission pursuant to
Rule 424(b) if, in the aggregate, the changes in volume and price represent no
more than a 20% change in the maximum aggregate offering price set forth in the
"Calculation of Registration Fee" table in the effective registration
statement;
(iii)
to include any material information with respect to the plan
of distribution not previously disclosed in this Registration Statement or any
material change to such information in this Registration Statement;
provided, however
, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the
information required to be included in a post-effective amendment by those
paragraphs is contained in periodic reports filed by us pursuant to Section 13 or
Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by
reference in this Registration Statement.
(2)
That, for the purpose of determining any liability under the Securities Act of
1933, each such post-effective amendment shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial bona fide offering thereof.
(3)
To remove from registration by means of a post-effective amendment any of the
securities being registered which remain unsold at the termination of the offering.
(b) We hereby undertake that, for purposes of determining any liability under the Securities Act of
1933, each filing of our annual report pursuant to Section 13(a) or Section 15(d) of the Securities
Exchange Act of 1934 that is incorporated by reference in this Registration Statement shall be
deemed to be a new registration statement relating to the securities offered herein, and the
offering of such securities at that time shall be deemed to be the initial bona fide offering
thereof.
(c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be
permitted to our directors, officers and controlling persons pursuant to the foregoing provisions,
or otherwise, we have been advised that in the opinion of the Securities and Exchange Commission
such indemnification is against public policy as expressed in the Securities Act of 1933 and is,
therefore, unenforceable. In the event that a claim for indemnification against such liabilities
(other than the payment by us of expenses incurred or paid by one of our directors, officers or
controlling persons in the successful defense of any action, suit or proceeding) is asserted by
such director, officer or controlling person in connection with the securities being registered, we
will, unless in the
opinion of our counsel the matter has been settled by controlling precedent, submit to a court
of
appropriate jurisdiction the question whether such indemnification by it is against public policy
as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such
issue.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it
has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and
has duly caused this Registration Statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of Austin, State of Texas on February 27, 2006.
ENCORE MEDICAL CORPORATION
By:
/s/ Harry L. Zimmerman
Harry L. Zimmerman
Executive Vice President—General Counsel
Each person whose signature appears below authorizes Kenneth W. Davidson or Harry L. Zimmerman
to execute in the name of each such person who is then an officer or director of the Registrant,
and to file any amendments to this Registration Statement necessary or advisable to enable the
Registrant to comply with the Securities Act of 1933, as amended, and any rules, regulations and
requirements of the Securities and Exchange Commission, in respect thereof, in connection with the
registration of the securities that are the subject of this Registration Statement, which
amendments may make such changes to such Registration Statement as such attorney may deem
appropriate.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration
Statement has been signed by the following persons in the capacities indicated on February 27,
2006.
SIGNATURE
TITLE
/s/ Kenneth W. Davidson
Chairman of the Board, Chief Executive Officer and Director
Kenneth W. Davidson
(Principal Executive Officer)
/s/ William W. Burke
Executive Vice President—Chief Financial Officer
William W. Burke
(Principal Financial Officer and Principal Accounting Officer)
/s/ Alastair J. Clemow
Director
Alastair J. Clemow
/s/ Joel S. Kanter
Joel S. Kanter
Director
/s/ Richard O. Martin
Richard O. Martin
Director
/s/ Karen R. Osar
Karen R. Osar
Director
Zubeen Shroff
Director
Bruce Wesson
Director
EXHIBIT INDEX
Exhibit Number
Description
4.1
Certificate of Incorporation of Encore Medical Corporation, as amended, including
Certificate of Designations, Preferences and Limitations of Series A Preferred
Stock (incorporated herein by reference to Exhibit 3.1 of Encore's Form 8-K filed
with the Commission on July 19, 2004).
4.2
Bylaws of Encore Medical Corporation (incorporated herein by reference to Exhibit
3.2 of Encore's Form 8-K filed with the Commission on July 19, 2004).
4.3
Form of certificate evidencing ownership of the Common Stock of Encore Medical
Corporation (incorporated herein by reference to Exhibit 4.7 of Encore's 10-K
filed with the Commission on March 30, 1998).
4.4
Non-Incentive Stock Option Agreement dated as of August 14, 2002 between Compex
Technologies, Inc. and Dan Gladney (incorporated by reference to Exhibit 10.12 to
the Compex Technologies, Inc. Annual Report on Form 10-K for the year ended June
30, 2003).
4.5
Non-Incentive Stock Option Agreement (with acceleration) dated as of August 14,
2002 between Compex Technologies, Inc. and Dan Gladney (incorporated by reference
to Exhibit 10.13 to the Compex Technologies, Inc. Annual Report on Form 10-K for
the year ended June 30, 2003).
4.6
Form of Non-Incentive Stock Option Agreement for Scott Youngstrom and Marshall
Masko.
4.7
Non-Incentive Stock Option Agreement, dated March 1, 2004 between Compex
Technologies, Inc. and Hawk Associates.
4.8
Non-Incentive Stock Option Agreement, dated April 23, 2004 between Compex
Technologies, Inc. and Sarah Ferguson.
4.9
Non-Incentive Stock Option Agreement, dated July 1, 2003 between Compex
Technologies, Inc. and Jerry Rice.
5.1
Opinion of Winstead Sechrest & Minick P.C. regarding the validity of the
securities being registered.
23.1
Consent of Winstead Sechrest & Minick P.C. (included as part of Exhibit 5.1).
23.2
Consent of KPMG LLP.
24.1
Power of Attorney (contained on the signature page of this registration statement).